The peptide regulatory landscape in 2026 is in active flux. After the FDA placed 19 popular peptides in Category 2 in late 2023, HHS Secretary RFK Jr. announced in February 2026 that New: An FDA decision to place 19 peptides on the unsafe list was supported by numerous documented safety concerns, former officials said. Even though demand for peptide therapies has exploded since then, Sermorelin: Understanding How It Works, Its Uses, and What People Need to Know Nirvanix Health Blog Medical Device FDA Approval Process [+Timeline]